CR20210493A - SUMINISTRO DE BIOMOLÉCULAS A PBMCs PARA MODIFICAR UNA RESPUESTA INMUNE - Google Patents

SUMINISTRO DE BIOMOLÉCULAS A PBMCs PARA MODIFICAR UNA RESPUESTA INMUNE

Info

Publication number
CR20210493A
CR20210493A CR20210493A CR20210493A CR20210493A CR 20210493 A CR20210493 A CR 20210493A CR 20210493 A CR20210493 A CR 20210493A CR 20210493 A CR20210493 A CR 20210493A CR 20210493 A CR20210493 A CR 20210493A
Authority
CR
Costa Rica
Prior art keywords
pbmcs
immune response
biomolecules
modify
delivery
Prior art date
Application number
CR20210493A
Other languages
English (en)
Inventor
Armon R Sharei
Matthew Booty
Emrah Ilker Ozay
Scott Loughhead
Howard Bernstein
Kelan Hlavaty
Defne Yarar
Katarina Blagovic
Carolyne Kelly Smith
Original Assignee
Sqz Biotechnologies Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sqz Biotechnologies Co filed Critical Sqz Biotechnologies Co
Publication of CR20210493A publication Critical patent/CR20210493A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0648—Splenocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4612—B-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/46449—Melanoma antigens
    • A61K39/464492—Glycoprotein 100 [Gp100]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/12—Animals modified by administration of exogenous cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2521/00—Culture process characterised by the use of hydrostatic pressure, flow or shear forces
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La presente solicitud proporciona células sanguíneas periféricas mononucleares (PBMCs) que comprenden un antígeno, métodos de producción de dichas PBMCs, y métodos de utilización de dichas PBMCs, tales como la modulación de una respuesta inmune en un individuo. En ciertas realizaciones, las PBMCs están acondicionadas al incubar la PBMC en presencia de un coadyuvante
CR20210493A 2019-02-28 2020-02-27 SUMINISTRO DE BIOMOLÉCULAS A PBMCs PARA MODIFICAR UNA RESPUESTA INMUNE CR20210493A (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962812225P 2019-02-28 2019-02-28
EP19161964 2019-03-11
US201962841089P 2019-04-30 2019-04-30
US201962886799P 2019-08-14 2019-08-14
US201962933304P 2019-11-08 2019-11-08
US201962948732P 2019-12-16 2019-12-16
PCT/US2020/020194 WO2020176789A1 (en) 2019-02-28 2020-02-27 Delivery of biomolecules to pbmcs to modify an immune response

Publications (1)

Publication Number Publication Date
CR20210493A true CR20210493A (es) 2022-01-17

Family

ID=72238527

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20210493A CR20210493A (es) 2019-02-28 2020-02-27 SUMINISTRO DE BIOMOLÉCULAS A PBMCs PARA MODIFICAR UNA RESPUESTA INMUNE

Country Status (17)

Country Link
US (1) US11692168B2 (es)
EP (1) EP3931309A4 (es)
JP (1) JP2022522351A (es)
KR (1) KR20210134353A (es)
CN (1) CN114127267A (es)
AU (1) AU2020228648A1 (es)
BR (1) BR112021016903A2 (es)
CA (1) CA3131701A1 (es)
CL (1) CL2021002258A1 (es)
CO (1) CO2021012581A2 (es)
CR (1) CR20210493A (es)
IL (1) IL285809A (es)
MX (1) MX2021010320A (es)
PE (1) PE20220379A1 (es)
SG (1) SG11202109333SA (es)
TW (1) TW202045717A (es)
WO (1) WO2020176789A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017041051A1 (en) 2015-09-04 2017-03-09 Sqz Biotechnologies Company Intracellular delivery of biomolecules to cells comprising a cell wall
BR112021016903A2 (pt) 2019-02-28 2021-11-03 Sqz Biotechnologies Co Administração de biomoléculas a pbmcs para modificação de uma resposta imune
CA3136296A1 (en) 2019-04-08 2020-10-15 Sqz Biotechnologies Company Cartridge for use in a system for delivery of a payload into a cell
CA3140029A1 (en) 2019-05-14 2020-11-19 Prometheus Biosciences, Inc. Tl1a patient selection methods, systems, and devices
AU2021272340A1 (en) * 2020-05-11 2022-12-08 F. Hoffmann-La Roche Ag Combination therapy with modified pbmcs and an immunoconjugate
JP2023539370A (ja) * 2020-09-02 2023-09-13 スクイーズ バイオテクノロジーズ カンパニー 有核細胞を使用してタンパク質に対するｈｌａ非依存的な免疫応答を刺激する方法
EP4271711A1 (en) 2020-12-29 2023-11-08 SQZ Biotechnologies Company Methods for treating cancers with modified pbmcs
CN116801719A (zh) * 2020-12-29 2023-09-22 Sqz生物技术公司 用于pbmc冷冻保存的调配物
US20220296691A1 (en) 2020-12-29 2022-09-22 Sqz Biotechnologies Company Methods for treating cancer with activating antigen carriers
CA3203709A1 (en) 2020-12-29 2022-07-07 Sqz Biotechnologies Company Formulations of activating antigen carriers
WO2023003907A1 (en) * 2021-07-19 2023-01-26 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Cellular therapies for cancer by inhibition of monocarboxylate transporter 11
EP4377447A1 (en) 2021-07-29 2024-06-05 SQZ Biotechnologies Company Methods to generate enhanced tumor infiltrating lymphocytes through microfluidic delivery
WO2023087009A1 (en) 2021-11-11 2023-05-19 Sqz Biotechnologies Company Methods to generate enhanced tumor infiltrating lymphocytes through microfluidic delivery
WO2024026491A2 (en) 2022-07-28 2024-02-01 Sqz Biotechnologies Company Enhanced antigen presenting cell formulations
WO2024026492A1 (en) 2022-07-28 2024-02-01 Sqz Biotechnologies Company Methods for treating cancer with enhanced antigen presenting cells

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2502621C3 (de) 1975-01-23 1978-09-14 Kernforschungsanlage Juelich Gmbh, 5170 Juelich Messung elastischer und dielektrischer Eigenschaften der Membran lebender Zellen
US4376634A (en) 1980-05-30 1983-03-15 Mallinckrodt, Inc. Assay kit having syringe, dilution device and reagents within sealed container
FR2569477B1 (fr) 1984-08-24 1987-01-02 Descartes Universite Rene Appareil et procede pour la determination de la deformabilite des globules rouges du sang
JP2720161B2 (ja) 1988-02-01 1998-02-25 株式会社アドバンス 細胞変形能測定装置
JP2685544B2 (ja) 1988-11-11 1997-12-03 株式会社日立製作所 血液フィルタおよび血液検査方法並びに血液検査装置
JP2532707B2 (ja) 1990-03-08 1996-09-11 佑二 菊池 血液回路及びこれを用いた血液測定装置及び血液測定方法
AU2002252073A1 (en) 2001-02-22 2002-09-12 The Scepens Eye Research Institute, Inc. Tolerogenic antigen presenting cells and in treating immune-inflammatory conditions
CN1604795B (zh) 2001-08-17 2010-05-26 科勒制药股份公司 具有提高的活性的组合基序免疫刺激寡肽
WO2003020039A1 (en) 2001-08-28 2003-03-13 Rush-Presbyterian-St. Luke's Medical Center Immune tolerance to predetermined antigens
EP2365325A1 (en) 2002-06-05 2011-09-14 Panasonic Corporation Device for measuring extracellular potential and method of manufacturing the device
US20060134067A1 (en) 2003-02-18 2006-06-22 Maxcyte, Inc. Loading of cells with antigens by electroporation
AU2003290460A1 (en) 2003-12-24 2005-07-14 Leiden University Medical Center Synthetic protein as tumor-specific vaccine
EP1746976B1 (en) 2004-05-03 2017-01-11 Merrimack Pharmaceuticals, Inc. Liposomes useful for drug delivery
US7968335B2 (en) 2004-06-17 2011-06-28 Ken Nakata Cell culturing method using biomechanical stimulation loading and system therefor
CN100591761C (zh) 2004-08-19 2010-02-24 加的夫大学学院咨询有限公司 呈递抗原的人γδT细胞的制备和在免疫治疗中的用途
US20060134772A1 (en) 2004-11-18 2006-06-22 The Regents Of The University Of California System for locating cells and for cellular analysis
US7704743B2 (en) 2005-03-30 2010-04-27 Georgia Tech Research Corporation Electrosonic cell manipulation device and method of use thereof
MX2007014474A (es) * 2005-05-17 2008-02-07 Univ Connecticut Composiciones y metodos para inmunomodulacion en un organismo.
WO2007067032A1 (en) 2005-12-09 2007-06-14 Academisch Medisch Cemtrum Bij De Universiteit Van Amsterdam Means and methods for influencing the stability of cells
US8293524B2 (en) 2006-03-31 2012-10-23 Fluxion Biosciences Inc. Methods and apparatus for the manipulation of particle suspensions and testing thereof
US20070249038A1 (en) 2006-04-21 2007-10-25 Andrea Adamo Microfluidic device for single cell targeted operations
JP2010500921A (ja) 2006-08-17 2010-01-14 マサチューセッツ・インスティテュート・オブ・テクノロジー マイクロ流体インジェクションのための方法と装置
WO2008098094A1 (en) 2007-02-06 2008-08-14 Network Biosystems, Inc. Devices and methods for the performance of miniaturized in vitro assays
US20080311140A1 (en) 2007-05-29 2008-12-18 Baylor College Of Medicine Antigen specific immunosuppression by dendritic cell therapy
FR2919804B1 (fr) 2007-08-08 2010-08-27 Erytech Pharma Composition et vaccin therapeutique anti-tumoral
GB0718160D0 (en) 2007-09-18 2007-10-24 Medical Res Council Methods
WO2009069418A1 (ja) 2007-11-28 2009-06-04 Konica Minolta Opto, Inc. 血液流動性計測装置及び血液流動性計測方法
US20090280518A1 (en) 2008-05-12 2009-11-12 Massachusetts Institute Of Technology System for high throughput measurement of mechanical properties of cells
JP5137129B2 (ja) 2008-07-23 2013-02-06 国立大学法人山口大学 血液細胞の力学的特性測定装置
US9115340B2 (en) 2008-08-08 2015-08-25 Agency For Science Technology & Research Microfluidic continuous flow device
CA2766907A1 (en) 2009-07-06 2011-01-13 Novartis Ag Self replicating rna molecules and uses thereof
US9364831B2 (en) 2009-08-08 2016-06-14 The Regents Of The University Of California Pulsed laser triggered high speed microfluidic switch and applications in fluorescent activated cell sorting
ES2600932T3 (es) 2009-10-27 2017-02-13 Erytech Pharma Composición para inducir una tolerancia inmunitaria específica
CN102791616B (zh) 2009-12-23 2015-07-29 西托维拉公司 用于粒子过滤的系统和方法
US20110293558A1 (en) 2010-03-22 2011-12-01 Massachusetts Institute Of Technology Material properties of t cells and related methods and compositions
ES2924027T3 (es) 2010-11-25 2022-10-04 Imcyse Sa Péptidos inmunogénicos para su uso en la prevención y/o tratamiento de enfermedades infecciosas, enfermedades autoinmunitarias, respuestas inmunitarias a alofactores, enfermedades alérgicas, tumores, rechazo de injerto y respuestas inmunitarias contra vectores virales usados para terapia génica o vacunación génica
AU2012326203B2 (en) 2011-10-17 2017-11-30 Massachusetts Institute Of Technology Intracellular delivery
WO2013185032A1 (en) 2012-06-07 2013-12-12 President And Fellows Of Harvard College Nanotherapeutics for drug targeting
WO2014165707A2 (en) 2013-04-03 2014-10-09 Memorial Sloan-Kettering Cancer Center Effective generation of tumor-targeted t-cells derived from pluripotent stem cells
AR095882A1 (es) 2013-04-22 2015-11-18 Hoffmann La Roche Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9
WO2015023982A1 (en) 2013-08-16 2015-02-19 Massachusetts Institute Of Technology Selective delivery of material to cells
RU2739794C2 (ru) * 2014-10-31 2020-12-28 Массачусетс Инститьют Оф Текнолоджи Доставка биомолекул в клетки иммунной системы
CN107002089B (zh) 2014-11-14 2021-09-07 麻省理工学院 化合物和组合物向细胞中的破坏和场实现的递送
CA2971626A1 (en) 2015-01-12 2016-07-21 Massachusetts Institute Of Technology Gene editing through microfluidic delivery
CA2988996A1 (en) 2015-07-09 2017-01-12 Massachusetts Institute Of Technology Delivery of materials to anucleate cells
EP3344747B1 (en) 2015-09-04 2022-11-09 SQZ Biotechnologies Company Intracellular delivery of biomolecules mediated by a surface with pores
WO2017041051A1 (en) 2015-09-04 2017-03-09 Sqz Biotechnologies Company Intracellular delivery of biomolecules to cells comprising a cell wall
ES2964746T3 (es) 2015-12-30 2024-04-09 Celgene Corp Métodos de producción de linfocitos T y linfocitos T producidos mediante el mismo
JP7033535B2 (ja) 2016-01-12 2022-03-10 スクイーズ バイオテクノロジーズ カンパニー 複合体の細胞内送達
CA3023099A1 (en) 2016-05-03 2017-11-09 Sqz Biotechnologies Company Intracellular delivery of biomolecules to induce tolerance
CN109415741A (zh) 2016-05-03 2019-03-01 Sqz生物技术公司 细胞内递送生物分子以诱导耐受性
US11422127B2 (en) * 2016-12-07 2022-08-23 Albany Medical College Ex vivo antigen and adjuvant pulsed peripheral blood mononuclear cells as a screening platform for candidate novel vaccines and candidate antigens
US20210317187A1 (en) 2017-12-05 2021-10-14 Sqz Biotechnologies Company Intracellular delivery of biomolecules to modulate antibody production
US20200332243A1 (en) 2017-12-20 2020-10-22 Sqz Biotechnologies Company System for delivery of a payload into a cell
TW202003019A (zh) 2018-03-12 2020-01-16 美商Ｓｑｚ生物科技公司 細胞內投遞生物分子以修改免疫反應之方法
WO2019178005A2 (en) * 2018-03-12 2019-09-19 Sqz Biotechnologies Company Methods for treating hpv-associated diseases
US20210113628A1 (en) 2018-03-12 2021-04-22 Sqz Biotechnologies Company Intracellular delivery of biomolecules to modify immune response
CA3115245A1 (en) 2018-10-04 2020-04-09 Sqz Biotechnologies Company Intracellular delivery of biomolecules to enhance antigen presenting cell function
US20220105166A1 (en) 2019-01-25 2022-04-07 Sqz Biotechnologies Company Anucleate cell-derived vaccines
BR112021016903A2 (pt) 2019-02-28 2021-11-03 Sqz Biotechnologies Co Administração de biomoléculas a pbmcs para modificação de uma resposta imune
CA3136296A1 (en) 2019-04-08 2020-10-15 Sqz Biotechnologies Company Cartridge for use in a system for delivery of a payload into a cell

Also Published As

Publication number Publication date
TW202045717A (zh) 2020-12-16
PE20220379A1 (es) 2022-03-18
US11692168B2 (en) 2023-07-04
CA3131701A1 (en) 2020-09-03
WO2020176789A1 (en) 2020-09-03
EP3931309A4 (en) 2022-12-21
EP3931309A1 (en) 2022-01-05
JP2022522351A (ja) 2022-04-18
MX2021010320A (es) 2021-11-12
CO2021012581A2 (es) 2022-01-17
US20200318066A1 (en) 2020-10-08
SG11202109333SA (en) 2021-09-29
AU2020228648A1 (en) 2021-10-14
CL2021002258A1 (es) 2022-06-17
KR20210134353A (ko) 2021-11-09
IL285809A (en) 2021-10-31
CN114127267A (zh) 2022-03-01
US20240132839A1 (en) 2024-04-25
BR112021016903A2 (pt) 2021-11-03

Similar Documents

Publication Publication Date Title
CR20210493A (es) SUMINISTRO DE BIOMOLÉCULAS A PBMCs PARA MODIFICAR UNA RESPUESTA INMUNE
PH12020551436A1 (en) Intracellular delivery of biomolecules to modify immune response
PH12020551437A1 (en) Methods for treating hpv-associated diseases
PH12019501227A1 (en) Synthetic immune receptors and methods of use thereof
MX2020008390A (es) Receptores de linfocitos t no restringidos a antígenos leucocitarios humanos (hla) y usos de los mismos.
WO2019008123A3 (en) CELLS, VERTEBRATES, POPULATIONS AND METHODS
EA201992469A1 (ru) Антигенспецифические иммунные эффекторные клетки
EP4257199A3 (en) Humanized anti-human-pd-1 antibody
BR112016014022A2 (pt) anticorpos anti-cd3, ácido nucleico isolado, vetor, célula hospedeira, método de produção do anticorpo anti-cd3, imunoconjugado, composição, uso do anticorpo anti-cd3, métodos de tratamento, métodos de intensificação da função imune e kit
MX2021006681A (es) Anticuerpos anti-claudina y usos de los mismos.
MX2023005612A (es) Celulas modificadas que expresan antigeno de membrana especifico de prostata (psma) o una forma modificada del mismo y metodos relacionados.
BR112021021843A2 (pt) Composições de proteína de fusão quimicamente projetada e métodos de uso das mesmas
WO2015112749A3 (en) Methods and compositions for antibody and antibody-loaded dendritic cell mediated therapy
CY1120220T1 (el) Μεθοδοι και κυτια για προσδιορισμο της καταστασης λοιμωξης απο φυματιωση
PH12020552181A1 (en) Constructs targeting prostate-specific membrane antigen (psma) and uses thereof
CU20210041A7 (es) Péptidos inmunogénicos con motivos de oxidorreductasa
AR119997A1 (es) Anticuerpos anti-klk7, anticuerpos anti-klk5, anticuerpos multiespecíficos anti-klk5 / klk7 y métodos de uso
CO2022007238A2 (es) Terapia de células t del receptor de antígeno quimérico
ZA202205927B (en) Anti-yellow fever virus antibodies, and methods of their generation and use
WO2018120843A9 (zh) 一种三功能分子及其应用
WO2019028422A9 (en) METHODS OF ACTIVATION OF IMMUNE CELLS
WO2019066617A3 (ko) 항 c-met 항체 및 이의 용도
MX2022000379A (es) Anticuerpos que se unen a celulas cancerosas yque dirigen radionucleidos a dichas celulas.
EA201992875A1 (ru) T-клетки со сниженным поверхностным фукозилированием и способы их получения и применения
WO2022051437A3 (en) Methods to stimulate hla-agnostic immune responses to proteins using nucleated cells